Dataset Information


The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.

ABSTRACT: PD-L1 expression and regulation by mesenchymal tumor cells remain largely undefined. Here, we report that among different EMT-activated MCF7 human breast cancer cell clones, PD-L1 was differentially upregulated in MCF7 sh-WISP2, MCF7-1001/2101, and MDA-MB-231 cells but not in MCF7 SNAI1 and MCF7 SNAI1-6SA cells. Mechanistic investigations revealed that siRNA silencing of ZEB-1, but not SNAI1, TWIST, or SLUG and overexpression of miR200 family members in MCF7 sh-WISP2 cells strongly decreased PD-L1 expression. Thus, we propose that PD-L1 expression in EMT-activated breast cancer cells depends on the EMT-TF involved in EMT activation. Interestingly, siRNA-mediated targeting of PD-L1 or antibody-mediated PD-L1 block restored the susceptibility of highly resistant MCF7 sh-WISP2 and MCF7-2101 cells to CTL-mediated killing. Additionally, these results provide a novel preclinical rationale to explore EMT inhibitors as adjuvants to boost immunotherapeutic responses in subgroups of patients in whom malignant progression is driven by different EMT-TFs.

PROVIDER: S-EPMC5283623 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5889210 | BioStudies
| S-EPMC7963182 | BioStudies
| S-EPMC6156376 | BioStudies
| S-EPMC7230232 | BioStudies
| S-EPMC3325969 | BioStudies
| S-ECPF-GEOD-35074 | BioStudies
| E-GEOD-35074 | BioStudies
| S-EPMC3506903 | BioStudies
| S-EPMC8125390 | BioStudies
2017-01-01 | S-EPMC5480087 | BioStudies